Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GLAUKOS CorpGKOS · Entity 3510 | Director | May 28, 2026 | June 23, 2026 |
| LENSAR, Inc.LNSR · Entity 6733 | Director | June 03, 2026 | June 05, 2026 |
| STAAR SURGICAL COSTAA · Entity 4851 | Director | June 20, 2024 | June 24, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GLAUKOS Corp
Report date May 28, 2026 · Filed June 23, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.52 · Expires 2036-05-28 | Direct | 2,987 |
Reported balance
After 2026-05-28 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 2,987 · Balance 2,987 F1: This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above. F2: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above.
F2: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.
LENSAR, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 110,368 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 17,421 · Balance 110,368 F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer.
STAAR SURGICAL CO
Report date June 20, 2024 · Filed June 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,352 |
Reported balance
After 2024-06-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 4,488 · Balance 15,352 F1: Reflects shares of restricted stock granted on June 20, 2024, pursuant to the Corporation's annual non-employee director equity compensation program for the 2024-2025 term. This equity award vests in full on the earlier of June 20, 2025, or the Corporation's 2025 Annual Meeting of Shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares of restricted stock granted on June 20, 2024, pursuant to the Corporation's annual non-employee director equity compensation program for the 2024-2025 term. This equity award vests in full on the earlier of June 20, 2025, or the Corporation's 2025 Annual Meeting of Shareholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Oyster Point Pharma, Inc.
Report date January 03, 2023 · Filed January 04, 2023
Section 16 reporting ended · disclosed 2023-01-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-01-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-01-03 · Disposition to issuer · Disposed 33,191 · Balance 3,573 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer was consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2) F2: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. Row 2 · 2023-01-03 · Disposition to issuer · Disposed 3,573 · Balance 0 F3: This line item represents restricted stock units held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested restricted stock units was accelerated and each restricted stock unit was canceled in exchange for a cash payment equal to the Per Share Price less applicable tax withholdings. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.63 · Expires 2032-06-05 | Direct | 0 |
Reported balance
After 2023-01-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-03 · Disposition to issuer · Disposed 5,359 · Balance 0 F5: Each vested option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration. F4: This line item represents stock options held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested stock options were accelerated, each such stock option became immediately exercisable and was canceled in exchange for a cash payment equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.74 · Expires 2031-06-06 | Direct | 0 |
Reported balance
After 2023-01-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-03 · Disposition to issuer · Disposed 5,199 · Balance 0 F5: Each vested option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration. F4: This line item represents stock options held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested stock options were accelerated, each such stock option became immediately exercisable and was canceled in exchange for a cash payment equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer was consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2)
F2: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.
F3: This line item represents restricted stock units held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested restricted stock units was accelerated and each restricted stock unit was canceled in exchange for a cash payment equal to the Per Share Price less applicable tax withholdings.
F4: This line item represents stock options held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested stock options were accelerated, each such stock option became immediately exercisable and was canceled in exchange for a cash payment equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings.
F5: Each vested option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2022 Filed May 27, 2022 23:59 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 15,616 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020017 · doc4.xml · derivative · entry 2 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,616 Underlying: Common Stock · 15,616 shares Expires 2032-05-25 F2 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 25, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| May 25, 2022 Filed May 27, 2022 23:59 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 4,285 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020017 · doc4.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,285 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on May 25, 2023, subject to the Reporting Person's continued service to the Issuer through the vesting date. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:59 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-001665 · tm221974-5_4seq1.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,342 F1 · security: Represents a grant of restricted stock units received by the reporting person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 3,837 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 00:27 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 2,000 | $51.66 | $103,320.00 |
DisclosureSEC source: 0001104659-21-102397 · tm2124630-2_4seq1.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Through the Saeman-Weisner Family Trust Disclosed balance after: 7,000 Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:51 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | GrantStock Option (Right to Buy) · Derivative | 5,199 | $0.00 Strike: $17.74 | $0.00 |
DisclosureSEC source: 0001209191-21-039342 · doc4.xml · derivative · entry 2 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,199 Underlying: Common Stock · 5,199 shares Expires 2031-06-06 F3 · derivative.exercise_date: The shares underlying the option vest as to one-twelfth (1/12th) of the shares on July 7, 2021 and monthly thereafter on the same day of the month as the grant date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date. Read SEC document |
| June 07, 2021 Filed Jun 10, 2021 00:51 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | GrantCommon Stock | 3,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039342 · doc4.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,191 F1 · kind: Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · shares: The shares underlying the RSU will vest on June 7, 2022, but will vest fully on the date of the next annual stockholder meeting held after the date of grant if not fully vested on such date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:03 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 2,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-077836 · tm2119039-8_4seq1.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,887 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 3,362 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:15 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 20,847 | $0.00 Strike: $7.49 | $0.00 |
DisclosureSEC source: 0000899243-21-020149 · doc4.xml · derivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,847 Underlying: Common Stock · 20,847 shares Expires 2031-05-18 F1 · derivative.exercise_date: The option vests in twelve (12) substantially equal monthly installments commencing June 18, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:09 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 13,445 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0000899243-21-011933 · doc4.xml · derivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,445 Underlying: Common Stock · 13,445 shares Expires 2031-03-12 F1 · derivative.exercise_date: The option vests as to one-third of the award on February 1, 2022 and, as to the remaining amount of the award, in twenty-four (24) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 21:10 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantStock Option (Right to Buy) · Derivative | 28,249 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0000899243-21-004177 · doc4.xml · derivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,249 Underlying: Common Stock · 28,249 shares Expires 2031-02-01 F1 · derivative.exercise_date: The option vests as to one-third of the award on February 1, 2022 and, as to the remaining amount of the award, in twenty-four (24) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 02:30 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 980 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-001756 · a4.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,505 F1 · security: Represents a grant of restricted stock units received by the reporting person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 4,880 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| June 08, 2020 Filed Jun 11, 2020 01:17 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | GrantCommon Stock | 6,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035750 · doc4.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,725 F1 · kind: Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · shares: The shares underlying the RSU vest as to one-twelfth (1/12th) of the RSU on July 8, 2020 and monthly thereafter on the same day of the month as the grant date; however, the shares underlying the RSU will vest fully on the date of the next annual stockholder meeting held after the date of grant if not fully vested on such date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date. Read SEC document |
| June 03, 2020 Filed Jun 6, 2020 00:58 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019055 · form4.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,525 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 5,062 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:31 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000906 · a4.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,625 F1 · security: Represents a grant of restricted stock units received by the reporting person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 3,815 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 22:52 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | GrantCommon Stock, par value $0.001 per share | 23,125 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-026596 · doc4.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,125 F1 · ownership.direct: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · ownership.direct: One quarter of the total number of shares subject to the grant shall vest one year after October 31,2019, and one sixteenth of the remaining shares shall vest, monthly thereafter, subject to continued service to the Issuer through each such vesting date. Read SEC document |
| May 30, 2019 Filed Jun 1, 2019 00:05 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 2,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-033241 · a4.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,463 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 3,830 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| January 02, 2019 Filed Jan 16, 2019 21:28 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 1,177 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-000316 · primarydocument.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,810 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Consists of 5,810 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 20:34 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 4,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-002760 · primarydocument.xml · nonDerivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,633 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Consists of 4,633 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 23:40 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $25.77 | $0.00 |
DisclosureSEC source: 0001562180-17-003886 · primarydocument.xml · derivative · entry 1 WEISNER AIMEE S · CIK 0001227308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-12-13 F1 · derivative.exercise_date: Granted pursuant to the Issuer's 2015 Omnibus Incentive Compensation Plan. Vests in full on May 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.